From: george church < Sent: Saturday, September 6, 2014 1:11 PM To: jeffrey E.; Richard Kahn Subject: Re: $200K The Androcyte business plan is =o patent products based on genomic (and epi-genomic) variants which are uni=ue to one or more supercentenarians (SC). Each such DNA variant can b= used to design and manufacture variant-specific RNAi molecules, proteins, =nd CRISPR guide-RNAs. The CRISPR is used for changing DNA in human ce=ls (stem cells, neurons, etc) to match the SC variant or reversible a=tivation or inhibition of the SC-impacted gene. Since we (Androcyte) =ave (by far) the most SC resources (including genomic variants already unde=going computational analyses) and have co-invented the CRISPR technol=gy, we are in unique position to develop these therapies swiftly. The=e products will be tested in animals and in partnerships with pharmaceutica= and skin care companies. Pharmaceuticals are becoming more costly du= to increasingly smaller (personalized) markets (e.g. Glybera at $1.6M per =reatment) -- Hence the prospect of Androcyte therapies that apply to every =erson (with access to reasonable health care) is a opportunity for cost red=ction and better margins due to huge markets. We will submit the firs= patent by Dec 2014 and begin CRISPR experiments and partnering discussions=immediately thereafter. Examples of potentia= partners for Androcyte: fiercebiotech.com/story/breaking-a=bvie-partners-googles-calico-lb-rd-operation-focused-aging/2014-09-03 =div> --George "Jeffrey E." <[email protected] <mailto:[email protected]» Date: Thu=sday, September 4, 2014 at 1:54 PM To: </=pan> george church < <mailto Subject: Re: F=: $200K > =gt;, Richard Kahn is there and was there a biz=plan? how does the co intend to make money? when/ ?=nbsp; the use of funds , appears more like a research grant than a fo= profit investment. On Thu, Sep 4, 2014 at 12:20 PM, george church &=t <mailto »<=span> wrote: Hopefully=this email will